Blank Andrew Scott 4

What Happened

• Blank Andrew Scott, a director of BioCardia, was granted 8,000 derivative shares (transaction type A — award) on 2026-07-06. The award shows a $0.00 acquisition price and no immediate cash outlay. The filing was made on 2026-07-07.

Key Details

• Transaction date: 2026-07-06; Form 4 filed: 2026-07-07 (timely within required reporting window).
• Instrument: Derivative award (code A) for 8,000 shares at $0.00.
• Vesting/exercise: Per the filing footnote, 100% of the shares vest and become exercisable on the one‑year anniversary of the grant (expected 2027-07-06), contingent on continued service.
• Shares owned after the transaction: not specified in the provided filing.
• No 10b5-1 plan, tax-withholding, or sale noted in this report; not marked as late.

Context

• This was an award/grant (acquisition of a derivative security) rather than an open-market purchase or a sale. The securities are not immediately vested or exercisable — they become exercisable only if the director remains a service provider through the one‑year cliff. Such awards are common for aligning executive/director incentives; the filing itself does not indicate the director’s intent to sell or hold future shares.